Financial Performance - The group's revenue for the fiscal year 2024 was approximately HKD 590.8 million, a decrease of about 41.0% compared to fiscal year 2023, primarily due to a reduction in revenue from COVID-19 related services by approximately HKD 509.0 million[1]. - The profit attributable to the company's owners for fiscal year 2024 was approximately HKD 24.2 million, a decrease of about HKD 156.6 million or 86.6% compared to fiscal year 2023[1]. - The basic earnings per share for fiscal year 2024 was approximately HKD 0.064, down from HKD 0.476 in fiscal year 2023[2]. - The total comprehensive income for the year was HKD 19.2 million, significantly lower than HKD 180.1 million in the previous year[2]. - The adjusted profit before tax for the group is HKD 26,564,000 in 2024, compared to HKD 238,816,000 in 2023, representing a decline of approximately 89%[13]. - The group reported a net profit of HKD 24,189,000 for 2024, a significant drop from HKD 180,839,000 in 2023, indicating a decline of around 87%[13]. - The income tax expense decreased from approximately HKD 58.0 million in FY2023 to about HKD 2.4 million in FY2024, resulting in a drop in the effective tax rate from approximately 24.3% to about 8.9%[41]. - Net profit for the year decreased from approximately HKD 180.8 million in FY2023 to about HKD 24.2 million in FY2024, with net profit margins of approximately 4.1% and 18.1% respectively[42]. Revenue Breakdown - The external customer revenue for the general medical services segment is HKD 398,388,000 in 2024, down from HKD 819,067,000 in 2023, indicating a decrease of about 51%[13]. - The revenue from primary healthcare services decreased by approximately HKD 420.7 million or 51.4% to about HKD 398.4 million in fiscal year 2024[33]. - The revenue from specialist medical services increased by approximately HKD 18.5 million or 16.1% to about HKD 134.0 million in fiscal year 2024[33]. - Comprehensive medical service revenue for 2024 was HKD 590,819,000, with general medical services contributing HKD 398,388,000 and specialist services contributing HKD 192,431,000[17]. Assets and Liabilities - Non-current assets totaled HKD 442.8 million for fiscal year 2024, down from HKD 466.5 million in fiscal year 2023[3]. - Current assets decreased to HKD 613.6 million in fiscal year 2024 from HKD 797.0 million in fiscal year 2023[3]. - The total assets of the group decreased to HKD 1,056,373,000 in 2024 from HKD 1,263,486,000 in 2023, a reduction of about 16%[14]. - The total liabilities for the group in 2024 are HKD 289,707,000, down from HKD 455,269,000 in 2023, reflecting a decrease of approximately 36%[14]. - Current liabilities were reduced to HKD 215.8 million in fiscal year 2024 from HKD 349.2 million in fiscal year 2023[3]. - The total equity attributable to the company's owners was HKD 766.7 million, down from HKD 808.2 million in fiscal year 2023[4]. Cost Management - Total costs of services provided were HKD 320,968,000 in 2024, down from HKD 408,510,000 in 2023, reflecting a cost reduction strategy[22]. - The cost of services provided decreased by approximately HKD 87.5 million or 21.4% to about HKD 321.0 million in fiscal year 2024[34]. - Administrative and other expenses decreased by approximately HKD 84.0 million or 24.1% from about HKD 348.0 million in FY2023 to approximately HKD 264.0 million in FY2024, mainly due to reductions in marketing expenses, depreciation, and impairment losses[38]. Dividends - The board proposed a final dividend of HKD 0.028 for fiscal year 2024, compared to HKD 0.16 for fiscal year 2023[1]. - The final dividend is subject to approval at the upcoming annual general meeting scheduled for December 2, 2024[77]. Operational Developments - The company focused on cost management and operational efficiency improvements while investing in IT infrastructure and digital capabilities to enhance customer experience and market coverage[45]. - The primary care division's overall revenue increased by approximately 28.5% in FY2024 compared to FY2023, excluding pandemic-related services[46]. - Patient visits in the primary care division rose by about 20.6% in FY2024 compared to FY2023, demonstrating resilience in meeting general healthcare demands[46]. - The company opened two new medical centers in FY2024, located in Lam Tin and Ngau Tau Kok, expanding its comprehensive healthcare service coverage[46]. - The introduction of specialized eye care services at the POLYEYE Eye Center aims to address various eye conditions and enhance the company's capabilities in ophthalmology[47]. Strategic Initiatives - The group is focusing on strategic investment in biomedical technology, particularly in developing gut microbiome technology based on precision medicine[52]. - The introduction of the "Ying Jian Online Store" membership program has improved brand awareness and customer loyalty, expanding market share[54]. - The "H2 Rewards" mobile app membership program has become a valuable asset for fostering customer relationships and encouraging active participation[55]. - The group aims to create value for stakeholders through continuous updates and enhancements of its products and services[53]. Corporate Social Responsibility - The company remains committed to corporate social responsibility by collaborating with the Hong Kong government to promote sustainable healthcare development[50]. - The group emphasizes the importance of corporate social responsibility and has been recognized for its contributions to community welfare[57]. Future Outlook - The company maintains a cautiously optimistic outlook for business growth and financial performance in the next fiscal year despite ongoing global economic uncertainties[61]. - The company aims to diversify its revenue sources through strategic partnerships, acquisitions, and market analysis to expand its customer base[61]. - The company is committed to digital transformation initiatives to enhance customer experience and operational efficiency, focusing on optimizing supply chains and data-driven decision-making[61].

Revenue Performance - The company recorded revenue of approximately HKD 295.2 million for the interim period of fiscal year 2024, a decrease of about HKD 386.1 million or 56.7% compared to the interim period of fiscal year 2023[17]. - Revenue from specialized medical services increased by approximately HKD 7.3 million or 12.5% to about HKD 65.2 million in the interim period of fiscal year 2024, driven by an increase in patient visits and average spending per visit[18]. - The company's primary healthcare services revenue decreased by approximately HKD 389.6 million or 66.2% to about HKD 198.9 million for the interim period of fiscal year 2024, primarily due to a reduction in revenue from COVID-19 related services[38]. - Revenue from dental services was approximately HKD 31.1 million in the interim period of fiscal year 2024, compared to HKD 34.9 million in the interim period of fiscal year 2023[34]. - The group reported a 47.3% increase in revenue from its general medical services, excluding COVID-19 related services, compared to the mid-year of the 2023 fiscal year[103]. - The primary revenue sources included General Medical Services at HKD 198,929,000, Specialist Medical Services at HKD 65,152,000, and Dental Services at HKD 31,109,000[195]. Profitability - The company's gross profit decreased by approximately HKD 327.3 million or 70.0% to about HKD 140.5 million, with the gross profit margin dropping from approximately 68.7% to 47.6%[22]. - The company’s net profit attributable to shareholders for the interim period of fiscal year 2024 was approximately HKD 20.0 million, down from HKD 268.1 million in the interim period of fiscal year 2023[30]. - The company's net profit for the interim period of fiscal year 2024 was approximately HKD 20.0 million, a decrease of about HKD 248.1 million or 92.5% compared to the same period in fiscal year 2023[46]. - The company’s net profit margin decreased from approximately 39.4% in the interim period of fiscal year 2023 to about 6.8% in fiscal year 2024[45]. - The adjusted profit before tax for the group was HKD 23,934,000, significantly down from HKD 325,092,000 in the previous year, reflecting a decline of 92.6%[197]. Expenses and Cost Management - Administrative expenses decreased by approximately HKD 14.7 million or 10.8% to about HKD 122.0 million, mainly due to a reduction in employee costs and depreciation[26]. - The total expenses for the group included employee benefits totaling HKD 60,860,000, down from HKD 70,183,000, indicating a reduction of 17.7%[197]. - The company incurred a total cost of medical supplies amounting to HKD 50,430,000, which increased from HKD 39,371,000 in the prior year, representing a rise of 28.5%[197]. Strategic Initiatives - The company acquired a medical center in Lam Tin during the interim period of fiscal year 2024 as part of its strategy to expand its network of medical service centers[31]. - The company plans to continue exploring new business opportunities in the rehabilitation sector as the Hong Kong government intends to expand its rehabilitation services to other industries[35]. - The company expanded its ophthalmology services in the H2 Health Center, which is expected to contribute to core revenue growth in the specialist medical division[52]. - The group aims to expand its service offerings in primary healthcare, focusing on family medicine, preventive care, and chronic disease management[76]. - The group has established a strategic partnership with The Chinese University of Hong Kong to provide professional rehabilitation and case management services for injured employees, indicating optimism about the rehabilitation market potential in Hong Kong[79]. - The group is implementing a prudent expansion strategy, ensuring that each acquisition is carefully evaluated and aligns with its strategic framework[66]. Operational Efficiency - The company maintained operational resilience and adaptability, indicating a significant step towards improving operational efficiency despite revenue declines[47]. - The group prioritizes cost restructuring and team optimization to enhance operational efficiency, streamlining staff due to reduced COVID-19 related services[67]. - The group is focused on continuous innovation and improvement, leveraging strategic alliances to create value for stakeholders and contribute to the overall development of the healthcare industry[71]. - The group is enhancing its digitalization and service optimization through a new generation integrated clinic operation platform, improving customer service and operational efficiency[72]. - The group remains committed to digitalization and automation to enhance operational efficiency and effectiveness[115]. Financial Position - The group's net current assets as of December 31, 2023, were approximately HKD 392.7 million, down from HKD 447.8 million as of June 30, 2023[117]. - Cash and cash equivalents, along with pledged deposits, amounted to approximately HKD 485.4 million as of December 31, 2023, compared to HKD 642.3 million as of June 30, 2023[117]. - The group's capital debt ratio was approximately 4.2% as of December 31, 2023, slightly down from 4.3% as of June 30, 2023[117]. - The total number of full-time employees decreased to 386 as of December 31, 2023, from 541 as of December 31, 2022[126]. - The company's net assets amounted to HKD 764,572,000, down from HKD 808,217,000, a decrease of about 5.4%[170]. Shareholder Information - The group has not declared any interim dividend for the fiscal year 2024[127]. - The company plans to distribute a final dividend of HKD 60,728,000, reflecting ongoing shareholder returns despite the financial adjustments[171]. - The major shareholder, Treasure Group Global Limited, holds 252,346,286 shares, representing 66.49% of the issued share capital[155]. Market Outlook - The group maintains a cautiously optimistic outlook for business growth and financial performance in the second half of the fiscal year 2024, despite ongoing global economic challenges[65]. - The group recognizes the significant expansion potential of private healthcare services due to the increasing market focus on health[70]. - The group aims to expand its market coverage and potential opportunities in the Greater Bay Area through its collaboration with Biomedical Technology Holdings Limited[93].

智通财经APP讯，盈健医疗(01419)发布截至2023年12月31日止6个月业绩，该集团期内取得收益2.95亿港元，同比减少56.67%;公司拥有人应占溢利2003.3万港元，同比减少92.53%;每股基本盈利5.3港仙。 公告称，集团于2024财年中期(截至2023年12月31日止6个月)的收益约为2.95亿港元，较2023财年中期减少约3.86亿港元或56.7%。该减少主要由于新型冠状病毒相关预防、检测、疫苗接种及外展服务产生的收益减少约4.53亿港元。撇除该等服务产生的收益后，集团的收益较2023财年中期增加约29.6%。 ...

Financial Performance - For the six months ended December 31, 2023, the group's revenue was approximately HKD 295.2 million, a decrease of about HKD 386.1 million or 56.7% compared to the same period in 2022[6]. - The gross profit for the same period was approximately HKD 140.5 million, a decrease of about HKD 327.3 million or 70.0%, with the gross profit margin dropping from approximately 68.7% to 47.6%[6]. - The profit attributable to the company's owners for the six months ended December 31, 2023, was approximately HKD 20.0 million, a decrease of about HKD 248.1 million or 92.5% compared to the previous year[6]. - Basic earnings per share for the period were approximately HKD 5.3, down from HKD 70.6 in the same period last year[6]. - The total comprehensive income for the period was HKD 17.1 million, significantly lower than HKD 267.6 million in the same period last year[4]. - Adjusted profit before tax for the six months ended December 31, 2023, was HKD 23,934,000, significantly lower than HKD 325,092,000 for the same period in 2022, indicating a decline of approximately 92.6%[20]. - The group reported a net profit of HKD 20,033,000 for the six months ended December 31, 2023, compared to HKD 268,112,000 for the same period in 2022, reflecting a decrease of about 92.5%[20]. - The group’s income tax expense for the six months ended December 31, 2023, was HKD 3,483,000, compared to HKD 55,745,000 for the same period in 2022, indicating a significant decrease of approximately 93.8%[20]. - The net profit for the first half of FY2024 decreased by approximately 92.5% to about HKD 20.0 million from approximately HKD 268.1 million in the first half of FY2023, resulting in a net profit margin decline from about 39.4% to approximately 6.8%[66]. Revenue Breakdown - Total revenue for the six months ended December 31, 2023, was HKD 295,190,000, a decrease from HKD 681,274,000 for the same period in 2022, representing a decline of approximately 56.6%[22]. - The revenue breakdown shows general medical services at HKD 198,929,000, specialist medical services at HKD 65,152,000, and dental services at HKD 31,109,000 for 2023[22]. - The group's revenue from primary healthcare services decreased by approximately HKD 389.6 million or 66.2% to about HKD 198.9 million for the interim period of fiscal year 2024, primarily due to a reduction in revenue from COVID-19 related prevention, testing, vaccination, and outreach services by approximately HKD 453.4 million[56]. - Revenue from specialized medical services increased by approximately HKD 7.3 million or 12.5% to about HKD 65.2 million in the interim period of fiscal year 2024, driven by an increase in patient visits and average spending per visit[84]. - The revenue from dental services decreased by approximately HKD 3.8 million or 10.8% to about HKD 31.1 million for the interim period of fiscal year 2024, mainly due to a decrease in patient visits[57]. - The revenue from general medical services increased by approximately 47.3% compared to the interim period of FY2023, excluding revenue from COVID-19 related services[111]. Cost and Expenses - The cost of services provided decreased by approximately HKD 58.8 million or 27.5% to about HKD 154.7 million for the interim period of fiscal year 2024, primarily due to a reduction in other direct costs such as contracted professional personnel[59]. - The gross profit decreased by approximately HKD 327.3 million or 70.0% to about HKD 140.5 million for the interim period of fiscal year 2024, with the gross profit margin declining from approximately 68.7% in the interim period of fiscal year 2023 to about 47.6%[60]. - Employee benefits expenses (excluding director remuneration) amounted to HKD 58.33 million in the first half of FY2024, down from HKD 67.93 million in the same period of FY2023[72]. - The administrative expenses decreased by approximately HKD 14.7 million or 10.8% from about HKD 136.7 million in the interim period of FY2023 to approximately HKD 122.0 million in the interim period of FY2024[129]. Assets and Liabilities - The group's total equity as of December 31, 2023, was HKD 764.6 million, down from HKD 808.2 million as of June 30, 2023[9]. - The group’s total non-current assets amounted to HKD 459,267,000 as of December 31, 2023, down from HKD 466,495,000 as of June 30, 2023[30]. - Current assets totaled HKD 612,697,000 as of December 31, 2023, compared to HKD 796,991,000 as of June 30, 2023, indicating a decrease of approximately 23.1%[30]. - The group’s total liabilities as of December 31, 2023, were HKD 220,028,000, compared to HKD 349,177,000 as of June 30, 2023, showing a reduction of approximately 37%[30]. - The group’s total assets less current liabilities amounted to HKD 851,936,000 as of December 31, 2023, down from HKD 914,309,000 as of June 30, 2023[30]. - As of December 31, 2023, the group's net current assets amounted to approximately HKD 392.7 million, down from HKD 447.8 million as of June 30, 2023[167]. - The group's cash and cash equivalents, along with pledged deposits, totaled approximately HKD 485.4 million as of December 31, 2023, compared to HKD 642.3 million as of June 30, 2023[167]. - The group's interest-bearing bank borrowings were approximately HKD 33.3 million as of December 31, 2023, a decrease from HKD 36.5 million as of June 30, 2023[167]. - The capital debt ratio was approximately 4.2% as of December 31, 2023, slightly down from 4.3% as of June 30, 2023[168]. Strategic Initiatives - The company plans to expand its recovery services into other sectors, leveraging its expertise to promote comprehensive development in the healthcare service area[1]. - The group aims to explore new business opportunities continuously, focusing on the recovery sector's medical services[1]. - The company aims to maintain a healthy financial position and has actively implemented various strategies to enhance operational efficiency and effectiveness[68]. - The group has rapidly adjusted its operational strategy to capture new opportunities and meet the evolving healthcare needs of patients[69]. - The group continues to prioritize digitalization and automation to optimize operational efficiency and effectiveness[166]. - The group aims to explore new business opportunities to meet changing customer demands despite challenges in primary healthcare service revenues due to COVID-19[164]. - The group is committed to enhancing market share, improving operational efficiency, and increasing stakeholder engagement to maintain its leading position in the healthcare industry[164]. - The group plans to implement a prudent expansion strategy, ensuring that each acquisition is carefully evaluated and aligns with its strategic framework[138]. - The group is actively seeking suitable acquisitions that align with its long-term business objectives to meet diverse business needs[148]. - The group has made significant progress in its strategic objectives during the fiscal year 2024, focusing on cost management and operational efficiency[130]. Operational Developments - The company expanded its ophthalmology medical and health services under the brand "Sheng Kang Hui H2," which is expected to contribute to core revenue growth in the specialized medical services segment[98]. - The company actively participated in the "Injury Employee Rehabilitation Pilot Program," which provided a stable income source and reinforced its commitment to delivering excellent rehabilitation services[99]. - The company opened a new medical center in Lam Tin as part of its strategy to establish a comprehensive network of strategic medical centers[96]. - The company operates 107 service points, including 54 medical centers, 1 day surgery center, 3 retail centers, and 1 community pharmacy as of December 31, 2023[103]. - The group maintained a stable performance in its flagship medical center, with an expanded service range including advanced ophthalmic medical and health procedures[126]. - The group has established a strategic partnership with the Chinese University of Hong Kong to provide professional rehabilitation and case management services for injured employees[116]. - The group remains optimistic about the potential of the rehabilitation market in Hong Kong and sees opportunities to expand its service offerings[116]. - The group continues to strengthen its collaboration with the Hong Kong government to support the development of primary healthcare systems, recognizing the growing demand for private healthcare services[151]. Workforce and Team Management - The group has reduced its workforce, with 386 full-time employees as of December 31, 2023, down from 541 a year earlier, and 403 part-time employees, down from 1,137[160]. - The group is committed to optimizing its healthcare team to ensure the provision of quality medical services and to retain top talent in a competitive healthcare industry[150]. - The healthcare professional team consists of 462 members, ensuring comprehensive and patient-centered medical and healthcare services[135]. Compliance and Governance - The company has adopted the standard code of conduct for securities trading by directors as per the listing rules, confirming compliance throughout the fiscal year 2024[177]. - The audit committee and management have reviewed the unaudited interim results for the fiscal year 2024, discussing internal controls and financial reporting matters[182]. - The company or any of its subsidiaries did not purchase, sell, or redeem any listed securities during the fiscal year 2024 interim period[183]. - There were no significant events affecting the company or its subsidiaries after the end of the fiscal year 2024 interim period[180]. Future Outlook - The group is cautiously optimistic about business growth and financial performance for the second half of fiscal year 2024, despite ongoing global economic challenges[137]. - The group is confident in its ability to achieve sustainable growth and provide long-term returns to shareholders[166].

Financial Performance - For the fiscal year 2023, the company's total revenue was approximately HKD 1,001.7 million, a decrease of about 10.7% compared to HKD 1,121.8 million in fiscal year 2022[22]. - The revenue from primary care services decreased by approximately HKD 135.1 million or 14.2% to about HKD 819.1 million, primarily due to reduced demand for COVID-19 related services[22]. - The revenue from specialist medical services increased by approximately HKD 11.0 million or 10.5% to about HKD 115.4 million, driven by an increase in patient visits and average spending per visit[23]. - The gross profit for fiscal year 2023 was approximately HKD 593.2 million, a decrease of about HKD 66.4 million or 10.1% from HKD 659.7 million in fiscal year 2022[27]. - The gross profit margin slightly increased from approximately 58.8% in fiscal year 2022 to about 59.2% in fiscal year 2023[27]. - The company's net profit for fiscal year 2023 was approximately HKD 180.8 million, a decrease of about HKD 194.5 million from HKD 375.3 million in fiscal year 2022[39]. - The effective tax rate increased from approximately 15.7% in fiscal year 2022 to about 24.3% in fiscal year 2023[38]. - The company's profit attributable to owners for the fiscal year 2023 was approximately HKD 180.8 million, a decrease of 51.8% compared to HKD 375.3 million in fiscal year 2022[40]. - Overall revenue for fiscal year 2023 decreased by approximately 10.7% compared to fiscal year 2022, primarily due to a significant drop in demand for pandemic-related services in the second half of the fiscal year[42]. Operational Developments - The company launched a large flagship health center, H2, which integrates various medical and health technology services, enhancing customer service quality[14]. - A new membership program was introduced to increase customer engagement and satisfaction, offering exclusive promotions and personalized recommendations[14]. - Strategic partnerships were established with United Medical Group and Biomedical Technology Holdings, aimed at enhancing operational efficiency and innovation in healthcare solutions[15]. - The company is focused on digital transformation, upgrading IT infrastructure and developing a new integrated clinic operation platform to improve customer experience[16]. - Investment in a smart health ecosystem is underway, leveraging advanced technology and data analytics to meet community health needs[18]. - The company aims to enhance its position as a leading healthcare service provider through continuous adaptation and strategic initiatives[12]. - The company plans to expand its ophthalmology services and continue digitalization and automation efforts to enhance operational efficiency[22]. - The company remains committed to providing high-quality healthcare services despite anticipated revenue challenges in the primary care segment for fiscal year 2024[22]. Market Trends and Challenges - The overall economic recovery post-COVID-19 has positively impacted the company's operations, although challenges and uncertainties remain in the global economic outlook[11]. - The group remains optimistic about the post-pandemic healthcare market potential in Hong Kong, driven by increased health awareness and rising visitor numbers[65]. - The group plans to enhance operational efficiency and expand service offerings in response to market trends and demands[65]. - For the fiscal year 2024, the group anticipates challenges in general healthcare service revenue due to the cessation of pandemic-related services but remains committed to providing high-quality healthcare and exploring new business opportunities[72]. Employee and Management Structure - The group employs a professional team of 558 members, including general practitioners, specialists, and other healthcare professionals, to provide comprehensive services[64]. - The total number of full-time employees decreased to 428 as of June 30, 2023, from 542 in 2022, while part-time employees decreased to 426 from 1,157[88]. - The company continues to recruit based on market conditions and business needs, with a focus on professional healthcare staff[88]. - The company has established a cautious evaluation standard for hiring healthcare professionals, considering experience, skills, and competencies[88]. - The management team is focused on developing comprehensive business plans to drive growth and operational efficiency[109]. Corporate Governance - The company has been expanding its board with independent non-executive directors to enhance governance and oversight[101][105]. - The company has adopted the corporate governance code as its governance framework, ensuring compliance with all applicable code provisions for the fiscal year 2023[116]. - The board of directors is responsible for approving the company's strategic planning and major financial matters, including significant transactions and investments[121]. - The company emphasizes the importance of independent external auditors in maintaining financial integrity and transparency[155]. - The audit committee consists of three independent non-executive directors, ensuring oversight of financial reporting and compliance[152]. Shareholder Relations - The company encourages ongoing communication with shareholders through various channels, including interim and annual reports[179]. - The company welcomes shareholder inquiries and feedback through its website, promoting transparency and open communication[180]. - The board has proposed a final dividend of HKD 0.16 per share for the fiscal year 2023, down from HKD 0.30 in fiscal year 2022[190]. - The company has maintained its core business of providing comprehensive and quality healthcare services without significant changes in the nature of its operations during fiscal year 2023[188]. - The company continues to enhance investor relations and communication with shareholders and potential investors[183].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全 部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Human Health Holdings Limited 盈健醫療集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1419） 截 至 二 零 二 三 年 六 月 三 十 日 止 年 度 之 年 度 業 績 公 告； 末 期 股 息 及 暫 停 辦 理 股 份 過 戶 登 記； 建 議 採 納 股 份 獎 勵 計 劃；及 建 議 修 訂 組 織 章 程 大 綱 及 細 則 財務摘要 • 本集團於二零二三財年之收益約為1,001.7百萬港元，較二零二二財年減 少約10.7%。 • 二零二三財年之毛利約為593.2百萬港元，較二零二二財年減少約10.1%。 毛利率由二零二二財年約58.8%輕微升至二零二三財年約59.2%。 • 本集團於二零二三財年之本公司擁有人應佔溢利約為180.8百萬港元， 較二零二二財年約375.3百萬港元減少約194.5百萬港元或約51.8%。 ...

Financial Performance - For the interim period of the fiscal year 2023, the company recorded a revenue of approximately HKD 681.3 million, an increase of about 75.3% compared to the interim period of the fiscal year 2022[5]. - The net profit attributable to the company's owners for the interim period of the fiscal year 2023 was approximately HKD 268.1 million, a significant increase of about 196.5% from approximately HKD 90.4 million in the same period of the previous year[3]. - The company's net profit margin improved from approximately 23.3% in the interim period of the fiscal year 2022 to approximately 39.4% in the interim period of the fiscal year 2023[3]. - The company's revenue for the six months ended December 31, 2022, was HKD 681,274,000, representing a 75.3% increase from HKD 388,544,000 in the same period of 2021[90]. - Gross profit for the same period was HKD 467,840,000, up 117.5% from HKD 215,495,000 year-on-year[90]. - The company reported a profit before tax of HKD 325,092,000, compared to HKD 108,226,000 in the previous year, reflecting a 200.3% increase[90]. - Net profit for the period was HKD 268,112,000, a substantial increase of 196.5% from HKD 90,428,000 in the prior year[90]. - Basic and diluted earnings per share were HKD 70.6 cents, compared to HKD 23.8 cents in the previous year, indicating a significant improvement[90]. Operational Developments - The company has established a large health mall in Tsim Sha Tsui, expected to commence operations in the first half of 2023, to provide a one-stop medical service and health technology-related services[21]. - The company has invested in IT infrastructure and digitalization to enhance stakeholder engagement[22]. - The company has a positive outlook on the rehabilitation treatment market in Hong Kong, supported by a strategic partnership with the Chinese University of Hong Kong Hospital[10]. - The company continues to focus on providing comprehensive, one-stop, and high-quality medical services[100]. Employee and Workforce - The company employed 541 full-time employees and 1,137 part-time employees as of December 31, 2022, compared to 446 full-time and 681 part-time employees a year earlier[29]. - The total employee benefits expenses, excluding directors' remuneration, rose to HKD 70,183,000 from HKD 55,202,000, an increase of 27.2%[112]. Financial Position - As of December 31, 2022, the company's net current assets were approximately HKD 560.1 million, an increase from approximately HKD 430.8 million as of June 30, 2022[25]. - The cash and cash equivalents increased significantly to HKD 542,923,000 from HKD 270,332,000, representing a growth of 100.5%[65]. - The operating cash flow for the six months ended December 31, 2022, was HKD 455,494,000, up from HKD 283,036,000 in the previous year, indicating a year-over-year increase of 60.7%[70]. - Trade receivables decreased to HKD 291,398,000 from HKD 422,336,000, a decline of 30.9%[65]. - Current liabilities totaled HKD 328,445,000, an increase from HKD 301,094,000, representing an increase of 9.1%[65]. - The total assets less current liabilities reached HKD 1,001,347,000, up from HKD 857,520,000, indicating an increase of 16.7%[65]. Share Options and Corporate Governance - The company has not adopted any share incentive plans as of December 31, 2022[36]. - The stock options granted can be exercised from June 1, 2021, to May 31, 2027, with 34% of the options available for exercise from June 1, 2023, to May 31, 2027[38]. - The company has a total of 6,850,000 shares held by beneficial owners, representing 1.80% of the issued shares[57]. - The board has reviewed the company's corporate governance practices to ensure compliance with applicable codes[48]. - The company has complied with all applicable corporate governance code provisions during the fiscal year 2023, except for a deviation from code provision C.2.1[48]. Market Outlook and Risks - The company maintains a cautious outlook for the second half of the fiscal year 2023 due to uncertainties in the economic recovery pace and anticipated decline in demand for pandemic-related services[17].

Financial Performance - For the fiscal year 2022, the company's revenue reached approximately HKD 1,121.8 million, representing a significant increase of about 71.3% compared to the fiscal year 2021[10]. - The company's revenue for the fiscal year 2022 reached approximately HKD 1,121.8 million, representing an increase of about 71.3% compared to HKD 654.7 million in the fiscal year 2021[23]. - Revenue from primary healthcare services increased by approximately HKD 485.2 million or 103.5% to about HKD 954.1 million, driven by rising demand for preventive, testing, vaccination, and outreach services[24]. - Revenue from specialist medical services decreased by approximately HKD 21.8 million or 17.2% to about HKD 104.4 million, primarily due to a reduction in patient visits[24]. - Revenue from dental services increased by approximately HKD 3.7 million or 6.2% to about HKD 63.2 million, attributed to an increase in average spending per visit[24]. - The company's gross profit increased by approximately HKD 283.0 million or 75.1% to about HKD 659.7 million in the fiscal year 2022, driven by revenue growth[28]. - The gross profit margin rose from approximately 57.5% in fiscal year 2021 to about 58.8% in fiscal year 2022, attributed to a higher proportion of revenue from general medical services[28]. - The profit attributable to the company's owners for fiscal year 2022 was approximately HKD 375.3 million, a significant increase of about 159.8% from HKD 144.5 million in fiscal year 2021[42]. - Other income and gains increased from approximately HKD 26.9 million to about HKD 32.3 million, mainly due to an increase in fair value changes of financial assets[34]. - Administrative expenses rose by approximately HKD 11.2 million or 4.9% to about HKD 241.8 million, primarily due to increases in property, plant, and equipment impairment[35]. Strategic Initiatives - The company plans to establish a new large health mall in Tsim Sha Tsui, covering over 38,000 square feet, to expand its service offerings[14]. - The establishment of the large health mall is expected to create new revenue streams and enhance the existing medical service network[14]. - The company plans to invest significant resources in the rehabilitation service sector to meet the growing demand in the Hong Kong market in the next fiscal year[15]. - A strategic partnership has been established with the Chinese University of Hong Kong to enhance the pilot program for injured employee rehabilitation, aiming to create greater synergy[15]. - The company is focused on digital transformation, planning to launch a new integrated clinic operation platform in the next fiscal year to improve stakeholder engagement and operational efficiency[19]. - The group is expanding its online business to optimize its e-commerce platform and provide a wider range of healthcare products and services[56]. - The group is committed to investing significant resources to upgrade and optimize its specialist medical centers' equipment and facilities in the next fiscal year[57]. - The group is exploring potential collaboration opportunities to enhance the service offerings of the health mall[81]. - The group is actively seeking partnerships to address the aging population issue by providing home care services for the elderly and those in need[87]. Community Engagement and Corporate Social Responsibility - The company continues to support the Hong Kong government's anti-epidemic measures while diversifying its primary care services[11]. - The company is committed to corporate social responsibility and actively supports community health initiatives[11]. - The group is actively involved in vaccination subsidy programs, providing flu and pneumonia vaccines, and promoting various vaccination activities[50]. - The group has been approved for a pilot program by the Labour Department to provide timely and coordinated private outpatient rehabilitation services for construction workers who have not returned to work after six weeks of injury[84]. - The group has pledged to continue participating in community health-related programs to offer convenient and comprehensive services[87]. Operational Efficiency and Technology - The company has a stable cash flow that allows for accelerated service expansion to meet various health service demands[14]. - The company emphasizes the use of advanced medical equipment, professional talent, cutting-edge technology, and big data analysis in its new health mall[14]. - The group is focusing on enhancing its information technology infrastructure and digital platforms to improve stakeholder engagement and client acquisition[58]. - The group introduced a new generation integrated clinic operation platform to manage B2C, B2B, and B2G interactions[61]. - The introduction of an "eHealth station" and an automated ticketing system is expected to improve customer experience by streamlining health check processes and reducing waiting times[80]. - The group is committed to continuous investment in digitalization, enhancing IT infrastructure, digital platforms, and upgrading medical equipment to improve operational efficiency and service experience[79]. Governance and Leadership - The company has adopted the corporate governance code as per the listing rules and has complied with all applicable provisions for the fiscal year 2022, except for a deviation from provision C.2.1[144]. - The Chairman and CEO roles are held by the same individual, Mr. Chan, which the board believes enhances internal leadership consistency and effective strategic planning[145]. - The board consists of seven directors, including four executive directors and three independent non-executive directors[153]. - The company has established procedures for directors to seek independent advice at the company's expense when necessary[150]. - The company has implemented appropriate liability insurance for directors and senior management to cover responsibilities arising from business operations[151]. - The board is committed to maintaining a high standard of corporate governance and compliance with relevant regulations[172]. - The board's diversity policy aims to achieve sustainable and balanced development by considering various factors including gender, age, cultural background, and ethnicity[191]. - The company emphasizes the importance of diversity in its board composition as a key element for achieving strategic goals[191]. Future Outlook - The group anticipates a cautious business growth outlook for the next fiscal year due to the ongoing impact of the pandemic, with expected demand for COVID-19 related services decreasing compared to fiscal year 2022[76]. - The company has outlined a future outlook with a projected revenue growth of 12% for the next fiscal year[138]. - The management team emphasized a commitment to improving operational efficiency, aiming for a 5% reduction in costs by the end of 2023[138]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% increase in market share by 2025[138]. - A strategic acquisition of a local dental service provider is anticipated to enhance service offerings and operational efficiency[138].

Revenue and Profitability - The company reported revenue of approximately HKD 388.5 million for the six months ended December 31, 2022, an increase of about HKD 157.9 million or 68.4% compared to the same period in 2021[17]. - Revenue from primary healthcare services increased by approximately HKD 159.7 million or 118.8% to about HKD 294.2 million, driven by the expansion of services related to prevention, screening, vaccination, and outreach[18]. - Gross profit increased by approximately HKD 106.5 million or 97.8% to about HKD 215.5 million, with the gross profit margin rising from approximately 47.2% to 55.5%[21]. - The company’s financial performance indicates a strong recovery and growth trajectory post-pandemic, with significant increases in both revenue and profitability metrics[21]. - Net profit for the first half of FY2022 rose by approximately HKD 73.5 million or 435.3% to about HKD 90.4 million, with a net profit margin increasing from 7.3% to 23.3%[33]. - The group recorded a significant profit growth during the first half of the 2022 fiscal year, reflecting a strong economic recovery in Hong Kong despite ongoing pandemic challenges[55]. Cost and Expenses - The cost of services provided increased by approximately HKD 51.4 million or 42.2% to about HKD 173.0 million, primarily due to increased direct costs associated with expanded services[20]. - The cost of medical supplies increased by 30.4% to HKD 44.4 million, reflecting higher expenses in this area[20]. - Administrative expenses decreased by approximately HKD 4.8 million or 4.3% to about HKD 107.6 million in the first half of FY2022, mainly due to the absence of trade receivables impairment[27]. - Financing costs for the first half of FY2022 were approximately HKD 1.1 million, down from HKD 1.7 million in the first half of FY2021, attributed to reduced interest expenses on lease liabilities[30]. Healthcare Services Expansion - The company plans to continue expanding its healthcare services, particularly in response to ongoing public health needs[19]. - The expansion of primary healthcare services included testing, vaccination, and outreach services, contributing to increased market share[38]. - The company actively participated in the COVID-19 vaccination program, enhancing its service offerings and community support[40]. - The group recognized a continuous increase in demand for disease prevention services, investing resources to provide health monitoring, guidance, and overall health enhancement programs[41]. - The group plans to expand its healthcare services by leasing a property in Tsim Sha Tsui with over 38,000 square feet to establish a large medical center, enhancing its service offerings[56]. Investments and Acquisitions - The group successfully acquired two properties in Hong Kong for its headquarters, which will provide a permanent location and save future rental expenses[47]. - The investment in the limited partnership amounted to RMB 30 million, with a 73.2% equity stake in Inno Healthcare as of December 31, 2021[69]. - The fair value of the investment in the limited partnership was approximately HKD 36.9 million, representing about 5.3% of the total assets as of December 31, 2021[70]. Shareholder Information and Governance - The company did not declare any interim dividend for the 2022 fiscal year, consistent with the previous year[85]. - The company has adopted the corporate governance code as per the listing rules and has complied with all applicable provisions during the fiscal year 2022, except for a deviation regarding the separation of the roles of Chairman and CEO[88]. - The Chairman and CEO roles are held by the same individual, Mr. Chan Kin Ping, which the board believes enhances internal leadership consistency and effective strategic planning[89]. - The company has implemented a share option scheme since February 17, 2016, with a total of 3,200,000 options granted, of which 2,490,000 remain unexercised as of December 31, 2022[93]. Financial Position - As of December 31, 2021, the group's net current assets were approximately HKD 196.8 million, down from HKD 230.6 million as of June 30, 2021[62]. - The group’s cash and cash equivalents, along with pledged deposits, amounted to approximately HKD 303.5 million as of December 31, 2021, compared to HKD 147.3 million as of June 30, 2021[62]. - The group’s interest-bearing bank borrowings were approximately HKD 45.1 million as of December 31, 2021, which included a mortgage loan of about HKD 35.4 million[62]. - The capital adequacy ratio was approximately 9.0% as of December 31, 2021, an increase from 2.8% as of June 30, 2021[63]. Employee Information - The group employed 446 full-time employees and 681 part-time employees as of December 31, 2021, compared to 330 full-time and 63 part-time employees a year earlier[75]. Taxation - Income tax expenses increased by approximately HKD 16.4 million or 1,173.1% to about HKD 17.8 million in the first half of FY2022, primarily due to an increase in taxable profits[32]. - The total tax expense for the period was HKD 17,798,000, a significant increase from HKD 1,398,000 in the same period last year[163].

Financial Performance - The company achieved encouraging performance in the fiscal year 2021 despite the disruptions caused by the COVID-19 pandemic[11]. - The company reported a revenue of approximately 654.7 million HKD for the fiscal year 2021, an increase of about 44.3% compared to 453.7 million HKD in the fiscal year 2020[22]. - The company recorded a profit of approximately HKD 144.5 million in FY2021, a significant increase of about HKD 184.8 million compared to a loss of approximately HKD 40.4 million in FY2020, resulting in a net profit margin improvement from -8.9% to 22.1%[39]. - Total revenue for FY2021 was approximately HKD 654.7 million, representing an increase of about 44.3% compared to FY2020[42]. - The company reported a significant increase in revenue, achieving a total of HKD 1.2 billion for the fiscal year 2021, representing a growth of 15% compared to the previous year[123]. Revenue Sources and Growth - Revenue from primary healthcare services increased by approximately 202.4 million HKD or 76.0% to about 469.0 million HKD in fiscal year 2021, driven by the expansion of services related to prevention, testing, vaccination, and outreach[23]. - The revenue from primary healthcare services increased by approximately 76.0% from HKD 266.5 million in FY2020 to HKD 469.0 million in FY2021[51]. - New product launches are expected to contribute an additional HKD 200 million in revenue, with a focus on innovative healthcare solutions[103]. - The company is expanding its market presence in D regions, aiming to capture a larger share of the healthcare market[115]. Cost Management and Expenses - The management implemented cost control measures, including short-term cost reduction strategies and long-term cost structure optimization[13]. - The cost of services provided increased by approximately 14.1 million HKD or 5.4% to about 278.0 million HKD in fiscal year 2021, primarily due to increases in direct costs and pharmaceutical costs[26]. - Administrative expenses rose by approximately HKD 22.2 million or 10.7% from about HKD 208.4 million in FY2020 to approximately HKD 230.6 million in FY2021, mainly due to increased trade receivables impairment and higher wages[33]. - The company has implemented cost-saving measures, resulting in a reduction of operational expenses by G%[119]. Strategic Initiatives and Services Expansion - The company expanded its primary care services to include pandemic-related services such as prevention, testing, vaccination, and outreach services[13]. - The company launched its own online shopping platform to meet the growing demand for health and pandemic-related products and services[13]. - The company plans to introduce booster vaccinations in the short term, with vaccination services potentially becoming a regular offering[15]. - The group aims to explore opportunities in various fields while maintaining its position as a market leader in providing high-quality services[22]. - The group is actively exploring and developing health-related products and services, including health check packages and vaccination services[49]. Market Outlook and Future Projections - The company anticipates a gradual decrease in overall demand for pandemic-related services as the pandemic situation eases[14]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12% based on current market trends and user acquisition strategies[103]. - The company has outlined a future outlook with a projected revenue growth of 20% for the next fiscal year, driven by new service offerings and market expansion strategies[123]. - The board remains cautiously optimistic about business growth and financial performance for the next fiscal year, despite uncertainties related to the pandemic[65]. Corporate Governance and Management - The company is committed to adhering to corporate governance standards, ensuring transparency and accountability in its operations[130]. - The board of directors has reviewed and confirmed compliance with all applicable corporate governance codes, reinforcing the company's commitment to ethical practices[130]. - The company has established procedures for directors to seek independent advice at the company's expense when necessary[136]. - The board of directors held seven meetings in the fiscal year 2021, including reviews of annual and interim financial statements and corporate governance matters[167]. Human Resources and Talent Management - The group recognizes the importance of attracting and retaining professional talent amid rising costs due to talent shortages and competition in the healthcare sector[70]. - The group employed 450 full-time employees as of June 30, 2021, an increase from 362 in 2020, and 479 part-time employees, up from 114 in 2020[85]. - The management team emphasized the importance of maintaining high-quality medical services, with ongoing training programs for healthcare professionals[124]. Community Engagement and Health Initiatives - The company actively participated in the Hong Kong government's community testing program, providing various testing options to the public[44]. - The company is committed to providing various preventive and early screening health services to enhance public health awareness[13]. - The group has been promoting various vaccination activities through social media to meet the rising demand for services such as cervical cancer and shingles vaccines[47].